Management of Pharmacologic Adverse Effects in Advanced Liver Disease.
Journal
Clinical drug investigation
ISSN: 1179-1918
Titre abrégé: Clin Drug Investig
Pays: New Zealand
ID NLM: 9504817
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
accepted:
24
03
2022
pubmed:
7
5
2022
medline:
22
6
2022
entrez:
6
5
2022
Statut:
ppublish
Résumé
As a consequence of the altered hepatic architecture in advanced liver disease, drug metabolism is modified by changes in pharmacokinetic and pharmacodynamic properties, leading to the appearance of adverse effects and drug interactions and increasing the risk of over- or underdosing of medications. However, there are no tests that accurately determine the degree of impairment of liver metabolic function; therefore, general recommendations are established based on the degree of hepatic extraction, degree of hepatic metabolism, and degree of protein binding. Although the hepatic toxicity of some frequently used drugs, such as acetaminophen, is well known, many health care professionals are unaware or not fully aware of the deleterious effects that other drugs can have on patients with advanced liver injury, as is the case for nonsteroidal anti-inflammatory drugs. It is very important to increase awareness among both health care professionals and patients with advanced liver disease to limit the use of inappropriate drugs and prevent drug-induced liver injury.
Identifiants
pubmed: 35522395
doi: 10.1007/s40261-022-01150-w
pii: 10.1007/s40261-022-01150-w
pmc: PMC9205818
doi:
Substances chimiques
Acetaminophen
362O9ITL9D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
33-38Informations de copyright
© 2022. The Author(s).
Références
Nat Rev Dis Primers. 2019 Aug 22;5(1):58
pubmed: 31439850
J Clin Epidemiol. 1993 Nov;46(11):1323-30
pubmed: 8229110
Eur J Gastroenterol Hepatol. 2019 Dec;31(12):1569-1576
pubmed: 31464786
Aliment Pharmacol Ther. 2013 Jun;37(12):1132-56
pubmed: 23638982
J Hepatol. 2019 Jun;70(6):1222-1261
pubmed: 30926241
Am J Gastroenterol. 2020 Feb;115(2):251-261
pubmed: 31789632
Eur J Clin Pharmacol. 2008 Dec;64(12):1147-61
pubmed: 18762933
Drugs. 2012 Aug 20;72(12):1645-69
pubmed: 22867045
Clin Pharmacol Ther. 2011 Jun;89(6):806-15
pubmed: 21544079
J Hepatol. 2015 Sep;63(3):593-600
pubmed: 25872166
BMJ Open. 2016 Oct 12;6(10):e012991
pubmed: 27733414
Rev Esp Enferm Dig. 2012 Apr;104(4):161-4
pubmed: 22537364
J Hepatol. 2021 Jul;75(1):86-97
pubmed: 33539847
Drug Saf. 2019 Apr;42(4):539-546
pubmed: 30357649
Hepatol Commun. 2019 Mar 18;3(5):620-631
pubmed: 31061951
Gastroenterology. 2015 Jun;148(7):1340-52.e7
pubmed: 25754159
Eur J Clin Pharmacol. 2002 Sep;58(6):435-40
pubmed: 12242604
Gastroenterology. 1982 Jan;82(1):97-105
pubmed: 6171479
J Hepatol. 1995 Feb;22(2):189-96
pubmed: 7790708
Drug Saf. 2018 Jun;41(6):603-613
pubmed: 29330714
Liver Int. 2015 Nov;35(11):2474-82
pubmed: 25809419
Drug Saf. 2005;28(6):529-45
pubmed: 15924505
Expert Opin Drug Saf. 2004 Jul;3(4):329-44
pubmed: 15268650
Hepatology. 2017 Jan;65(1):391
pubmed: 27618725
Hepatology. 2021 Jun;73(6):2429-2440
pubmed: 32911564